26-Jul-2024
No headlines found.
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate ABIO, MODN, DPSI, AIRC
PRNewswire (Wed, 5-Jun 3:54 AM ET)
PRNewswire (Tue, 4-Jun 8:17 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, HIBB, ABIO, HMNF
PRNewswire (Thu, 23-May 12:28 PM ET)
Kuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law Firm
PRNewswire (Wed, 22-May 3:08 PM ET)
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PIK, CHX, MODN, ABIO
Globe Newswire (Sat, 11-May 9:22 AM ET)
Business Wire (Fri, 10-May 6:34 PM ET)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates NVEI, CHX, KTRA, ABIO
Globe Newswire (Sat, 27-Apr 8:49 AM ET)
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Arca Biopharma trades on the NASDAQ stock market under the symbol ABIO.
As of July 26, 2024, ABIO stock price climbed to $3.14 with 122,431 million shares trading.
ABIO has a beta of -0.47, meaning it tends to be less sensitive to market movements. ABIO has a correlation of 0.01 to the broad based SPY ETF.
ABIO has a market cap of $45.53 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ABIO stock traded as high as $4.49 and as low as $1.56.
The top ETF exchange traded funds that ABIO belongs to (by Net Assets): VTI, VXF, IWC, DFAT, DFSU.
ABIO has outperformed the market in the last year with a return of +53.9%, while the SPY ETF gained +21.0%. However, in the most recent history, ABIO shares have underperformed the stock market with its stock returning -12.3% in the last 3 month period and -6.3% for the last 2 week period, while SPY has returned +7.5% and -2.8%, respectively.
ABIO support price is $2.91 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABIO stock will trade within this expected range on the day.